HC Wainwright Reiterates “Buy” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $200.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 81.80% from the company’s current price.

Several other research analysts have also recently weighed in on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $222.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday. Truist Financial reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Finally, UBS Group dropped their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

JAZZ traded up $0.72 during trading on Friday, hitting $110.01. The company had a trading volume of 693,769 shares, compared to its average volume of 597,957. The company has a market cap of $6.94 billion, a PE ratio of 22.68, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.85. Jazz Pharmaceuticals has a 1-year low of $103.01 and a 1-year high of $146.70. The business has a 50-day moving average of $116.44 and a 200-day moving average of $121.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, analysts forecast that Jazz Pharmaceuticals will post 16.24 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the transaction, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in JAZZ. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter. Cape Investment Advisory Inc. raised its position in shares of Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 292 shares during the period. Covestor Ltd lifted its stake in shares of Jazz Pharmaceuticals by 676.5% during the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 345 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 37.1% during the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares during the period. Finally, Spire Wealth Management grew its stake in Jazz Pharmaceuticals by 128.6% in the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 238 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.